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  A b s t r a c t
   Background:  Recent studies consistently reported Alzheimer’s disease (AD) and, to a lower ex-
tent, mild cognitive impairment (MCI) to be accompanied by reduced cerebrospinal fluid (CSF) 
levels of      -amyloid. However, how these changes are related to brain morphological alterations 
is so far only partly understood.   Methods:  CSF levels of      -amyloid (1–42) were examined with 
respect to cerebral atrophy in 23 subjects with MCI, 16 patients with mild-to-moderate     Alzhei-
mer’s disease (AD) and 15 age-matched controls by using magnetic resonance imaging and vox-
el-based morphometry (VBM).  Results:  When contrasted with the controls,     -amyloid (1–42) lev-
els were significantly lower (p   !   0.05) in patients with MCI and even more so in the AD patients. 
This effect was significantly associated with reduced gray matter densities in both the right and 
left hippocampal head based on the results of a VBM analysis across the entire sample.   Conclu-
sion:  Our finding confirms the results of previous studies and suggests that both the decrease in 
     -amyloid (1–42) and the development of hippocampal atrophy coincide in the disease process.
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  Introduction
    It is generally accepted that the aggregation of      -amyloid (1–42) and the formation of 
senile plaques in Alzheimer’s disease (AD) correspond with decreased cerebrospinal fluid 
(CSF) levels of      -amyloid (1–42) in patients with mild cognitive impairment (MCI) and AD 
compared with healthy controls   [1]  . Therefore, decreased      -amyloid (1–42) levels confer an 
increased risk for progression from MCI to AD in longitudinal studies  [2] . According to neu-
ropathological studies,      -amyloid deposits are not evenly distributed throughout the brain 
but rather follow a characteristic pattern during the clinical course of AD   [3, 4]  . Unlike the 
distribution of neurofibrillary tangles, which were primarily observed in allocortical regions 
of the medial temporal lobe according to the model of Braak and Braak   [5]  , the initial depo-
sition of      -amyloid plaques is exclusively found in neocortical areas, i.e. frontal, temporal 
and parietal cortical fields, respectively. However, neuropathological studies in the field did 
not consider a number of important clinical parameters, such as education or severity of de-
mentia. Using magnetic resonance imaging (MRI), clinical studies found decreased CSF lev-
els of      -amyloid (1–42) in patients with mild-to-moderate AD to be significantly correlated 
with temporal lobe   [6]   and hippocampal atrophy   [7]  , respectively. Significant correlations 
between      -amyloid (1–40) and cerebral changes did not arise. Hence, one may hypothesize 
that the decrease in     -amyloid (1–42) corresponds to the development of hippocampal atro-
phy in the disease process.
    In a previous MRI study, we investigated CSF levels of the microtubule-associated tau 
protein (total tau protein) and of a hyperphosphorylated isoform [phospho-tau (181)] with 
respect to cerebral morphology in 39 patients with MCI or AD. Voxel-based morphometry 
(VBM) was used for image analyses, which allowed for user-independent detection of struc-
tural alterations throughout the entire brain. Elevated CSF levels of both biomarkers were 
associated with reduced gray matter density in temporal, parietal and frontal regions. In the 
MCI patients, increased CSF levels of phospho-tau (181) protein, but not total tau protein, 
were associated with pronounced atrophy in the right hippocampus  [8] . Longitudinal studies 
of MCI patients   [2, 9]   yielded an increased risk of progression to AD with higher CSF tau 
protein concentrations. From a clinical perspective, these associations are likely to reflect 
two sides of the same medal since hippocampal atrophy refers to declarative memory deficits 
  [10–12]   which typically exacerbate with progression from MCI to AD as one of the core 
symptoms of the disease.
    In the present MRI study, we investigated the potential relationship between levels of 
CSF      -amyloid (1–42) and gray matter changes in patients with MCI or mild-to-moderate 
AD and healthy controls. We studied the same group of patients examined in our previous 
study   [8]  . Groups were carefully matched for age and education. Using the protocol of our 
previous study, VBM was applied to consider gray matter changes in any part of the brain 
  [8]  . Decreased CSF      -amyloid (1–42) concentrations were expected to be associated with 
hippocampal atrophy indicating a coincidence of the respective changes in the disease pro-
cess.
  Patients  and  Methods
  P a t i e n t s
  A total of 54 patients were included in our previous and in our current study: 23 patients 
with MCI defined according to the concept of aging-associated cognitive decline (AACD) 
  [13–15]  , 16 patients with probable AD according to NINCDS-ADRDA (National Institute of 
Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and 395
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Related Disorders Association)   [16]   and 15 otherwise healthy controls. Of the 54 patients, 
only 8 MCI patients were available for follow-up examinations.
  The AACD concept considers deficits in various neurocognitive domains, such as mem-
ory and learning, attention and concentration, thinking, language and visuospatial function. 
AACD subjects were identified based on different criteria such as their performance on a 
standardized test of cognition involving at least 1 of the aforementioned domains with a 
score of at least 1 unit of standard deviation below the age-adjusted norm; an exclusion of 
dementia and any medical, neurologic or psychiatric disorders associated with cognitive de-
terioration, as determined by patient history and/or clinical examination, and normal ac-
tivities of daily living.
  All participants were recruited consecutively at the Section of Geriatric Psychiatry at the 
University of Heidelberg, Germany. The Institutional Review Board of the University ap-
proved the study protocol. Written informed consent was obtained from the participants 
after the planned procedures had been fully explained by a geriatric psychiatrist.
  Clinical  Examination
    The clinical examination included ascertainment of personal medical history, family 
history and detailed physical, neurological and neuropsychological examinations. None of 
the participants had a lifetime history of neurologic or severe medical illness, head injury or 
substance abuse. Global cognitive deficits were assessed using the Mini Mental State Exam-
ination  [17]  and cognitive performance was investigated based on an extensive neuropsycho-
logical test battery as described elsewhere   [18]  .
  C S F   A n a l y s i s
    All CSF samples (250      l in polypropylene tubes) were obtained by lumbar puncture be-
tween 10 and 12 a.m. as part of the routine diagnostic procedure. The maximum time period 
between MRI and lumbar puncture was 6 days. Immediately after lumbar puncture, samples 
were frozen in liquid nitrogen without centrifugation and stored at –80    °    C. Concentrations 
of      -amyloid (1–42) were measured using an enzyme-linked immunosorbent assay [ELISA 
Innotest      -amyloid (1–42) Ag kit; Innogenetics, Ghent, Belgium], as described elsewhere 
  [19]  . For the discrimination of incipient AD from controls, sensitivity and specificity of CSF 
     -amyloid (1–42) were determined as 86 and 90%, respectively   [1]  .
  MRI  Acquisition
    MRI data were obtained at the German Cancer Research Center with a 1.5-tesla Mag-
netom Symphony scanner (Siemens Medical Solutions). To exclude secondary causes of de-
mentia and ischemic changes, we performed a 2-dimensional T  2 -weighted fast spin echo 
(TR = 4,500 ms, TE = 90 ms) sequence in axial orientation. For structural analysis, a T  1 -
weighted 3-dimensional magnetization prepared rapid gradient echo sequence was per-
formed with the following parameters: 126 coronar slices, image matrix 256   !   256, voxel 
size 0.98   !   0.98   !   1.8 mm, TR = 10 ms, TE = 4 ms.
    In addition, vascular changes in the T  2 -weighted sequences were quantified according to 
the European Task Force on Age-Related White Matter Changes rating scale   [20]   and inter-
preted in relation to the anamnestic risk factors. Amyloid angiopathic changes were evaluated 
on the gradient echo sequences. Patients showing pronounced microvascular changes (age-
related white matter changes of grade 2 or higher) were excluded from further evaluation.
  Voxel-Based  Morphometry
    SPM2 software (www.fil.ion.ucl.ac.uk/spm) was used for VBM. Initially, all structural 
images were carefully screened for artifacts, the origin was placed on the anterior commis-396
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sure and the images were reoriented manually to approximate the anterior and posterior 
commissure to the horizontal plane.
    For pre-processing of imaging data, the VBM protocol proposed by Good et al.   [21]   was 
applied to minimize the probability of misclassifications within the tissue segmentation. 
Briefly, this method comprised the following steps:
    –  creation of a customized group and tissue-specific template;
    –  segmentation of MRI (in native space) into tissue classes, followed by a series of 
additional automated morphological operations to remove unconnected non-brain 
voxels from the segments;
    –  normalization of the gray and white matter images to the group-specific templates;
    –  reapplication of calculated normalization parameters to the structural images and 
reslicing them to a voxel size of 1   !   1   !   1 mm  3 ;
    –  resegmentation of normalized structural images [owing to local volume effects 
(growing or shrinking) in nonlinear spatial normalization, a voxel-wise multiplication 
with the Jacobian determinant, derived from normalization parameters, was 
performed to preserve the volume of a particular volume], and
    –  smoothing of tissue segments with a 10-mm full-width at half-maximum Gaussian 
kernel   [22] .
  Statistical  Analysis
    SPSS for Windows version 14 (SPSS Inc.) was used for statistical analysis of demographic 
and clinical data. Values of p   !   0.05 were considered to be significant. Regional correlations 
were assessed between local gray matter density values and      -amyloid (1–42) in CSF using 
voxel-wise regression analysis. The resulting T-map was thresholded for a significance level of 
p  !   0.001 uncorrected and a spatial extent of 200 voxels. To avoid false-positive findings caused 
by potential confounders known to affect brain morphology, ‘effects of no interest gray matter 
maps’ were modeled using regressors for age, sex and level of education. By creating mask im-
ages, we were able to exclude the regions related to these nuisance variables from the analysis.
  In a second VBM analysis, potential associations between CSF levels of     -amyloid (1–42) 
and gray matter density within the AACD group were tested separately. To improve statisti-
cal power in this relatively small sample, the AACD group was divided into those subjects 
with normal and those with reduced      -amyloid (1–42) levels, respectively, and hereafter a 
two-sample t test as implemented in SPM2 software was applied. AACD subjects were as-
signed to the corresponding groups after determination of values for     -amyloid (1–42) levels 
by the 10th percentile of the control group (International Federation of Clinical Chemistry, 
1987). According to a cutoff value of 904 pg/ml, 12 AACD subjects had normal and 11 AACD 
subjects had reduced      -amyloid (1–42) CSF levels.
    To address an effect of AD diagnosis as the explanation for the observed correlation, we 
examined gray matter differences between controls and patients with AD using a t test as 
implemented in SPM2 software.
  R e s u l t s
    Demographic characteristics and CSF      -amyloid (1–42) levels are summarized in   ta-
ble 1  . While the diagnostic groups showed only minor, non-significant differences with re-
spect to age, gender and level of education, mean MMSE scores differed significantly with 
the MCI patients ranking between the AD patients and the controls. Similarly, mean CSF 
levels of      -amyloid (1–42) were lowest in the AD patients followed by the MCI patients and 
the controls (p   !   0.01).397
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    VBM analyses across the entire sample revealed significant associations between lower 
CSF      -amyloid (1–42) concentrations and reduced gray matter densities in both the right 
and left hippocampal head (  fig. 1  ;   table 2  ). No significant correlations were found within 
single diagnostic groups.
  Discussion
    The present study yielded two major findings: (i) a confirmation that CSF levels of      -
amyloid (1–42) decrease with transition from normal aging to MCI and even more so with 
progression from MCI to manifest AD, and (ii) an indication that this process corresponds 
to progressive hippocampal atrophy rather than to changes in other cerebral sites.
  The decrease in     -amyloid (1–42) in AD was already described in the early 1990s  [6]  and 
assigned to the binding of the peptide to senile plaques. Dilution effects were considered as 
an additional explanation, because brain atrophy in AD is accompanied by an enlargement 
  Table  1.  Demographics and      -amyloid (1–42) levels in healthy controls, AACD and AD (cf.   [8] )
 Variable   Controls  (1)
  (n  =  15) 
 AACD  (2)
  (n  =  23) 
 AD  (3)
  (n  =  16) 
 F 
  value 
 d.f.  p 
value 
 Duncan 
  test  (5%) 
 Female/male  ratio  9/6  13/10  9/7   NS 
 Age,  years  68.9 8  6.7 69.4  8  5.4 68.6  8  6.9  0.09    2, 51  0.91    1 = 2 = 3 
 Education,  years  10.13 8  1.81 10.17  8  1.78 10.38  8  1.93  0.08    2, 51  0.92    1 = 2 = 3 
 MMSE  29.20 8  0.78 26.04  8  1.69 20.13  8  2.96    83.92    2, 51    <0.001    1 > 2 > 3 
 A    1–42, pg/ml   1,086.60 8  134.29   937.83  8  220.39   791.81  8  233.29  7.76    2, 51    <0.01    1 > 2 > 3 
 Means  8   SD. A     =     -Amyloid; d.f. = degrees of freedom; MMSE = Mini Mental State Examination; NS = non-significant 
(     2  test). 
  Fi g .   1.   Associations between CSF      -amyloid (1–42) concentrations and gray matter densities (across the 
entire sample).
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of internal and external CSF spaces. However, only one of the structural neuroimaging stud-
ies   [6, 7, 23–25]   conducted so far yielded significant correlations between      -amyloid (1–42) 
and the volume of the CSF spaces.
    Our finding of a significant association of decreased CSF      -amyloid (1–42) levels and 
hippocampal atrophy is in accordance with the longitudinal study of Herukka et al.  [23]  who 
investigated the association of CSF biomarkers with medial temporal lobe atrophy and the 
prognostic value of these measures to predict AD in a group of 21 MCI patients. Already at 
baseline, the 8 patients in whom symptoms converted from MCI to manifest AD showed 
lower CSF levels of      -amyloid (1–42) and higher tau and phospho-tau (181) protein levels 
than patients with stable MCI. These changes corresponded to more pronounced atrophic 
changes in all cerebral sites considered. While the significant associations between tau and 
phospho-tau (181) levels and hippocampal and left entorhinal cortex volumes could be dem-
onstrated across the entire group, the respective correlations of      -amyloid (1–42) reached 
significance for the left hippocampal volume in the progressive group only.
    In a large multicenter study, Schuff et al.   [24]   investigated rates of hippocampal loss, de-
termined by successive MRI scans, with respect to CSF      -amyloid (1–42), tau and phospho-
tau (181) levels in 112 cognitively normal elderly controls, 226 MCI patients and 96 AD pa-
tients. The MCI and AD groups showed significant hippocampal volume losses over 6 
months, which even accelerated towards the 1-year follow-up. In the MCI patients, increased 
rates of hippocampal volume loss were associated with lower CSF levels of     -amyloid (1–42). 
Similarly, De Leon et al.   [26]   observed a significant association between      -amyloid (1–42) 
CSF levels, phospho-tau (231) CSF levels and hippocampal atrophy in their longitudinal 
study of 7 patients with MCI. The prognostic values of the respective variables was under-
lined by Bouwman et al.   [27]   who found a 4-fold higher risk for MCI patients with both me-
dial temporal lobe atrophy and abnormal CSF values to develop manifest AD than those 
without the respective changes.
    On the basis of the ADNI (AD Neuroimaging Initiative) database, Fjell et al.   [25]   inves-
tigated CSF levels of      -amyloid (1–42), tau and phospho-tau (181) protein as well as brain 
morphometry in patients with MCI or AD and healthy controls over the course of 1 (n = 205) 
and 2 years (n = 176), respectively. CSF biomarker levels did not account for differences in 
brain morphometry at baseline between the diagnostic groups. In the MCI group, CSF bio-
marker levels were significantly associated with longitudinal atrophy rates in several regions, 
including the hippocampus, amygdala, parahippocampal gyrus, entorhinal cortex, inferior 
and medial temporal cortex as well as increased volumes of the lateral ventricles. Interest-
ingly, even MCI patients with levels of      -amyloid (1–42) comparable with controls showed 
more atrophy than the controls. The authors concluded that morphometric changes in MCI 
and AD are not secondary to CSF biomarker changes and that the two types of biomarkers 
reflect complementary processes.
  Table 2.  Anatomical structures showing significant positive correlation between gray matter density and 
     -amyloid (1–42) concentration in patients with AD, subjects with AACD and healthy controls
  Anatomical structure    Cluster size (voxel)    T value    Peak coordinates (x, y, z) 
 Left  hippocampal  head   1,581   4.67   –28,  –12,  –16 
  Right hippocampal head  311    4.02    28, 8, 16 
  Height threshold p < 0.001, uncorrected; extent threshold = 200 voxels. 399
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    The studies cited above support the association between lower CSF levels of      -amyloid 
(1–42) and hippocampal atrophy, which was originally described by our group   [7]   in 32 pa-
tients in all stages of AD using manual segmentation. Complementing these cross-sectional 
findings, decreased      -amyloid (1–42) levels may also herald an increase in atrophic changes 
in the clinical course. As emphasized by Fjell et al.   [25]  ,      -amyloid (1–42) levels do not only 
predict hippocampal atrophy but also atrophic changes of all medial temporal substructures, 
including an enlargement of the adjacent CSF spaces in MCI.
  In a previous study, we investigated the cerebral correlates of elevated total tau and phos-
pho-tau (181) protein CSF levels in the same sample using an identical VBM protocol  [8] . The 
respective changes did not only refer to hippocampal atrophy but also involved the parahip-
pocampal gyrus, the medial and superior temporal cortex, the left inferior parietal cortex, 
and the left orbital gyrus cortex. According to Fjell et al.   [25]  , the different patterns of cere-
bral correlates of      -amyloid (1–42), total tau and phospho-tau (181) protein levels, respec-
tively, corroborate the hypothesis that the two types of biomarkers yield complementary 
information.
    Major limitations of our study were the modest sample size and the cross-sectional de-
sign. Age, gender and educational level have to be considered as potential confounding fac-
tors. However, the correlations obtained between      -amyloid (1–42) and density reductions 
in MRI were corrected for these variables. Noteworthy, correlations between CSF measures 
and brain morphology did not remain significant after correction for multiple comparisons. 
However, our findings are clearly in accordance with previous independent neuroimaging 
studies. Since the hippocampus has been shown to be particularly involved in AD pathology, 
it is unlikely that the present results are false positive, especially since they are confined to 
the medial temporal lobe. As shown in   figure 2  , atrophic brain changes were not restricted 
to the hippocampus but also involved bilateral temporal, parietal and other neocortical areas 
typically related to AD pathology.
  In summary, this study revealed that patients with AD and – to a lesser extent – patients 
with MCI show significantly lower CSF levels of      -amyloid (1–42) than healthy controls. In 
these patients, lower CSF      -amyloid (1–42) levels are significantly associated with hippo-
campal atrophy rather than with changes in other cerebral sites.
  Fi g .   2 .   Atrophic brain changes 
(AD vs. controls); for further de-
tails please refer to the discus-
sion section. 400
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